Belimumab was recently shown to reduce disease activity in patients with systemic lupus erythematosus. This observation raises important questions about where belimumab might best fit into the treatment paradigm for this disease, and how the agent might compare to other biologic agents currently under investigation.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Wallace, D. J. et al. A phase II randomized, double-blind, placebo-controlled, dose-ranging study of belimumab of patients with active systemic lupus erythematosus. Arthritis Rheum. 61, 1168–1178 (2009).
Appel, G. B. et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J. Am. Soc. Nephrol. 20, 1103–1112 (2009).
Merrill, J. T. et al. The efficacy and safety of abatacept in SLE: results of a 12-month exploratory study. Presented at the American College of Rheumatology 2008 Annual Scientific Meeting.
Merrill, J. T. et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study (EXPLORER). Presented at the American College of Rheumatology 2008 Annual Scientific Meeting.
Furie, R. et al. Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR study. Arthritis Rheum. 60 (Suppl.), S429 (2009).
Navarra, S. et al. Belimumab, a BLyS-specific inhibitor, reduced disease activity, flares, and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 study. Presented at the American College of Rheumatology 2009 Annual Scientific Meeting.
GlaxoSmithKline and Human Genome Sciences announce positive results in second of two phase 3 trials of Benlysta in systemic lupus erythematosus. GlaxoSmithKline [online] (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D. Wofsy declares that he has acted as a consultant for Bristol-Myers Squibb, Biogen Idec, Vifor Pharma and Merck Serono. M. Dall'Era declares no competing interests.
Rights and permissions
About this article
Cite this article
Dall'Era, M., Wofsy, D. Belimumab for systemic lupus erythematosus: breaking through?. Nat Rev Rheumatol 6, 124–125 (2010). https://doi.org/10.1038/nrrheum.2010.20
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2010.20
This article is cited by
-
Treatment of proliferative lupus nephritis: a slowly changing landscape
Nature Reviews Nephrology (2011)
-
Development trends for human monoclonal antibody therapeutics
Nature Reviews Drug Discovery (2010)
-
Genomics drugs in clinical trials
Nature Reviews Drug Discovery (2010)
